Association of the Time to Immune Checkpoint Inhibitor (ICI) Initiation and Outcomes With Second Line ICI in Patients With Advanced Urothelial Carcinoma

1. Talukder, R.
2. Makrakis, D.
3. Lin, G.I.
4. Diamantopoulos, L.N.
5. Dawsey, S.
6. Gupta, S.
7. Carril-Ajuria, L.
8. Castellano, D.
9. de Kouchkovsky, I.
10. Jindal, T.
11. Koshkin, V.S.
12. Park, J.J.
13. Alva, A.
14. Bilen, M.A.
15. Stewart, T.F.
16. McKay, R.R.
17. Tripathi, N.
18. Agarwal, N.
19. Vather-Wu, N.
20. Zakharia, Y.
21. Morales-Barrera, R.
22. Devitt, M.E.
23. Cortellini, A.
24. Fulgenzi, C.A.M.
25. Pinato, D.J.
26. Nelson, A.
27. Hoimes, C.J.
28. Gupta, K.
29. Gartrell, B.A.
30. Sankin, A.
31. Tripathi, A.
32. Zakopoulou, R.
33. Bamias, A.
34. Murgic, J.
35. Fröbe, A.
36. Rodriguez-Vida, A.
37. Drakaki, A.
38. Liu, S.
39. Lu, E.
40. Kumar, V.
41. Lorenzo, G.D.
42. Joshi, M.
43. Isaacsson-Velho, P.
44. Buznego, L.A.
45. Duran, I.
46. Moses, M.
47. Barata, P.
48. Sonpavde, G.
49. Wright, J.L.
50. Yu, E.Y.
51. Montgomery, R.B.
52. Hsieh, A.C.
53. Grivas, P.
54. Khaki, A.R.
55. Mostrar todos los/as autores/as +